Category-wise Analysis By Product, Ozempic Dominates the GLP-1 Receptor Agonist Market Ozempic (semaglutide) dominates with 32.1% share of the global market in 2025 , due to its strong efficacy in both glycemic control and weight management
Elevated free IGF-1 in epidemiological studies is associated with increased prostate, pre-menopausal breast, and colorectal cancer risk, though those associations involve chronically elevated endogenous IGF-1, not short-duration pharmaceutical use [8]
There is no benefit to weight loss during pregnancy, and it may cause harm
Thats why we offer glutathione IVs as part of our mobile IV services
If you're deficient in B12, injections can increase your energy and well-being (which may lead to weight loss)
But the risk could be significant: Contaminated drugs from compounding pharmacies have in the past led to dire consequences for patients, including deaths